前列腺癌是最常见的恶性肿瘤之一，在导致男性死亡的癌症中排第三位。雄激素受体是核受体超家族的配体依赖式转录因子，其信号通路在前列腺癌的发生发展以及侵袭转移中起到重要作用。雄激素受体并不是独立的介导雄激素的刺激，而是需要与其他辅助因子的相互作用来实现。.课题组前期研究发现了雄激素受体的一个相互作用蛋白LMO1，并在在前列腺癌组织中高表达，说明LMO1可能是与前列腺癌发生发展相关的重要基因。LMO1是只包含LIM结构域的LMO家族成员。研究证实LMO1与急性T淋巴细胞白血病和神经母细胞瘤的形成发展密切相关。但LMO1与前列腺癌的关系尚未有报道。.本研究中我们拟以LMO1为枢纽建立基因表达调节网络，采用双报告基因系统、染色质免疫沉淀技术、RNAi等方法研究前列腺癌中LMO1对雄激素受体调控的机制及其与前列腺癌的相关性，对揭示前列腺癌发病机制的研究具有重要的理论意义和潜在的实践价值。.

Prostate cancer is the most frequently diagnosed malignancy and the third leading cause of cancer mortality in men. The androgen receptor (AR) is a member of the nuclear hormone receptor family of transcription factors. The androgen receptor signaling axis plays an essential role in the development, function and homeostasis of male urogenital structures including the prostate gland and contributes to the initiation, progression and metastatic spread of prostate cancer.AR does not act independently to mediate responses to androgen, but requires interaction with a distinct profile of cofactors..Our present study indentified a protein LMO1, which interacted with AR in vitro, and was detected upregulated in expression in cancerous tissue of prostate. LMO1 is a member of the LIM-only (LMO) family of LIM domain. Studies have confirmed that LMO1 has been in close association with the genesis and development of T-ALL and neuroblastoma. But, it has not been reported that LMO1 have relationship with prostate cancer and AR..The further investigation of the mechanism of LMO1 on AR transcriptional regulation in prostate cancer and the relationship between LMO1 and prostate cancer, some technique including Dual-Luciferase Assay System, ChIP, and RNAi will be performed to provide theory basis for pathogenesis and therapeutics of prostate cancer..